Suchergebnisse - "Proto-Oncogene Proteins p21(ras) genetics"

The mutagenic forces shaping the genomes of lung cancer in never smokers

Autoren: Marcos Díaz-Gay Tongwu Zhang Phuc H. Hoang et al.

Weitere Verfasser: Marcos Díaz-Gay Tongwu Zhang Phuc H. Hoang et al.

Quelle: Nature
r-FISABIO. Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Díaz-Gay, M, Zhang, T, Hoang, P H, Leduc, C, Baine, M K, Travis, W D, Sholl, L M, Joubert, P, Khandekar, A, Zhao, W, Steele, C D, Otlu, B, Nandi, S P, Vangara, R, Bergstrom, E N, Kazachkova, M, Pich, O, Swanton, C, Hsiung, C A, Chang, I-S, Wong, M P, Leung, K C, Sang, J, McElderry, J P, Hartman, C, Colón-Matos, F J, Miraftab, M, Saha, M, Lee, O W, Jones, K M, Gallego-García, P, Yang, Y, Zhong, X, Edell, E S, Santamaría, J M, Schabath, M B, Yendamuri, S S, Manczuk, M, Lissowska, J, Świątkowska, B, Mukeria, A, Shangina, O, Zaridze, D, Holcatova, I, Mates, D, Milosavljevic, S, Kontic, M, Bossé, Y, Rothberg, B E G, Christiani, D C, Gaborieau, V, Brennan, P, Liu, G, Hofman, P, Yang, L, Nowak, M A, Shi, J, Rothman, N, Wedge, D C, Homer, R, Yang, S-R, Pesatori, A C, Consonni, D, Lan, Q, Zhu, B, Chanock, S J, Choi, J, Alexandrov, L B & Landi, M T 2025, 'The mutagenic forces shaping the genomes of lung cancer in never smokers', Nature, vol. 644, no. 8075, pp. 133-144. https://doi.org/10.1038/s41586-025-09219-0

Schlagwörter: Male, Lung Neoplasms/genetics, Genome, Human/genetics, Mutation/genetics, ErbB Receptors/genetics, Tobacco Smoke Pollution/adverse effects, Non-Smokers, Middle Aged, Air Pollution/adverse effects, Mutagenesis/genetics, Proto-Oncogene Proteins p21(ras)/genetics, Europe, Genome, Human/genetics, Humans, Adenocarcinoma/genetics, Tumor Suppressor Protein p53/genetics, Female, Aged

Zugangs-URL: https://fisabio.portalinvestigacion.com/publicaciones/19141
https://hdl.handle.net/11511/115373
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105009633828&origin=inward

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118

Autoren: Kramer-Drauberg, Maximilian Petrini, Ettore Mira, Alessia et al.

Weitere Verfasser: Kramer-Drauberg, Maximilian Petrini, Ettore Mira, Alessia et al.

Quelle: Mol Oncol
Molecular Oncology, Vol 19, Iss 2, Pp 311-328 (2025)

Schlagwörter: Cancer Research, cysteine modification, KRAS protein, human, Oncologie, NSCLC, Sciences de la santé humaine, Proto-Oncogene Proteins p21(ras)/genetics, redox regulation, Proto-Oncogene Proteins p21(ras), Mice, Cysteine/metabolism, oncogene, Cell Line, Tumor, Genetics, Humans, Animals, Cysteine, Human health sciences, RC254-282, KRAS C118, ROS, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oncology, Mutation, Molecular Medicine, Proto-Oncogene Proteins p21(ras)/metabolism, Reactive Oxygen Species, Oxidation-Reduction, Research Article

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39838816
https://doaj.org/article/84af2962b2cd4f30905eaf3ff2e7ea61
https://hdl.handle.net/2268/328671
https://doi.org/10.1002/1878-0261.13798
https://hdl.handle.net/2318/2049950
https://doi.org/10.1002/1878-0261.13798

KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma

Autoren: Jan Budczies Eva Romanovsky Martina Kirchner et al.

Quelle: Br J Cancer
British journal of cancer, vol. 131, no. 3, pp. 524-533

Schlagwörter: Male, Aged, 80 and over, Adult, 0301 basic medicine, Lung Neoplasms, Adenocarcinoma of Lung, Middle Aged, Prognosis, Article, Aged, 80 and over [MeSH], Aged [MeSH], Lung Neoplasms/genetics [MeSH], 692/53/2423, Cohort Studies [MeSH], Proto-Oncogene Proteins p21(ras)/genetics [MeSH], Immunotherapy/methods [MeSH], Male [MeSH], Adenocarcinoma of Lung/genetics [MeSH], 631/67/1612/1350, Lung Neoplasms/immunology [MeSH], 631/114/2415, Female [MeSH], Adenocarcinoma of Lung/drug therapy [MeSH], Mutation [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], Adenocarcinoma of Lung/immunology [MeSH], Tumor Suppressor Protein p53/genetics [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], 631/208/69, Biomarkers, Tumor/genetics [MeSH], Prognosis [MeSH], Lung Neoplasms/pathology [MeSH], Lung Neoplasms/drug therapy [MeSH], Adenocarcinoma of Lung/pathology [MeSH], article, Proto-Oncogene Proteins p21(ras), Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Humans, Tumor Suppressor Protein p53/genetics, Mutation, Proto-Oncogene Proteins p21(ras)/genetics, Female, Adenocarcinoma of Lung/genetics, Adenocarcinoma of Lung/drug therapy, Adenocarcinoma of Lung/immunology, Adenocarcinoma of Lung/pathology, Immune Checkpoint Inhibitors/therapeutic use, Lung Neoplasms/genetics, Lung Neoplasms/drug therapy, Lung Neoplasms/pathology, Lung Neoplasms/immunology, Aged, Biomarkers, Tumor/genetics, Immunotherapy/methods, Biomarkers, Tumor, Immunotherapy, Tumor Suppressor Protein p53, Immune Checkpoint Inhibitors

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38866964
https://serval.unil.ch/notice/serval:BIB_0BE58CAF6E6A
https://serval.unil.ch/resource/serval:BIB_0BE58CAF6E6A.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_0BE58CAF6E6A7
https://repository.publisso.de/resource/frl:6518703

APOBEC affects tumor evolution and age at onset of lung cancer in smokers

Autoren: Tongwu Zhang Jian Sang Phuc H. Hoang et al.

Quelle: Nat Commun
Nature Communications, Vol 16, Iss 1, Pp 1-17 (2025)
Zhang, T, Sang, J, Hoang, P H, Zhao, W, Rosenbaum, J, Johnson, K E, Klimczak, L J, McElderry, J, Klein, A, Wirth, C, Bergstrom, E N, Díaz-Gay, M, Vangara, R, Colon-Matos, F, Hutchinson, A, Lawrence, S M, Cole, N, Zhu, B, Przytycka, T M, Shi, J, Caporaso, N E, Homer, R, Pesatori, A C, Consonni, D, Imielinski, M, Chanock, S J, Wedge, D C, Gordenin, D A, Alexandrov, L B, Harris, R S & Landi, M T 2025, 'APOBEC affects tumor evolution and age at onset of lung cancer in smokers', Nature Communications, vol. 16, no. 1, pp. 4711. https://doi.org/10.1038/s41467-025-59923-8

Schlagwörter: Male, Lung Neoplasms/genetics, APOBEC Deaminases/metabolism, Lung Neoplasms, Science, Article, Proto-Oncogene Proteins p21(ras)/genetics, Minor Histocompatibility Antigens, Proto-Oncogene Proteins p21(ras), Minor Histocompatibility Antigens/genetics, Cytidine Deaminase, Smoking/adverse effects, Humans, APOBEC Deaminases, Age of Onset, Aged, Smokers, Smoking, Proteins, Middle Aged, Cytidine Deaminase/genetics, Mutagenesis, Mutation, Tumor Suppressor Protein p53/genetics, Female, Tumor Suppressor Protein p53, DNA Damage

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40394004
https://doaj.org/article/12e3261774da4cda8ae34b9030ca60c4

Differential unfolded protein response regulation in KRAS silencing sensitive and innately resistant colorectal cancer cells

Autoren: Martins, Flávia Machado, Ana L. Carvalho, Joana et al.

Quelle: Sci Rep
Scientific Reports, Vol 15, Iss 1, Pp 1-15 (2025)

Schlagwörter: Proteomics, Science, Drug Resistance, Apoptosis, Article, Cell Line, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Apoptosis/genetics, Cell Line, Tumor, Humans, Gene Silencing, Wnt Signaling Pathway, Neoplastic, Tumor, Neoplasm/genetics, Unfolded Protein Response/genetics, HCT116 Cells, Colorectal Neoplasms/genetics, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Drug Resistance, Neoplasm, Unfolded Protein Response, Medicine, Colorectal Neoplasms

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40274922
https://doaj.org/article/2ac9e7d15b51492a9e9add08427f3361

Use of the Malaria Protein VAR2CSA for the Detection of Small Extracellular Vesicles to Diagnose Adenocarcinoma

Autoren: Yaru Zhao Chenlei Wen Qi Wang et al.

Quelle: J Extracell Vesicles
Journal of Extracellular Vesicles, Vol 14, Iss 4, Pp n/a-n/a (2025)
Zhao, Y, Wen, C, Wang, Q, Qing, Y, Tondi, S, Reina, C, Šabanović, B, Chang, C Y-Y, Lai, C-H, Wang, H, Agerbaek, M Ø, Clausen, T M, Gustavsson, T, Theander, T G, Salanti, A, Meny, C C, Shen, B, Aicher, A, Tang, J & Heeschen, C 2025, ' Use of the malaria protein VAR2CSA for the detection of small extracellular vesicles to diagnose adenocarcinoma ', Journal of Extracellular Vesicles, vol. 14, no. 4, e70067 . https://doi.org/10.1002/jev2.70067

Schlagwörter: Male, Short Communication, pancreatic ductal adenocarcinoma, Antigens, Protozoan, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Extracellular Vesicles, Antigens, Protozoan/metabolism, Cell Line, Tumor, Biomarkers, Tumor, Humans, Pancreatic Neoplasms/diagnosis, oncofetal chondroitin sulfate, Early Detection of Cancer, Aged, QH573-671, Chondroitin Sulfates, Extracellular Vesicles/metabolism, Middle Aged, Early diagnosis, recombinant malaria protein, Pancreatic Neoplasms, Biomarkers, Tumor/blood, Chondroitin Sulfates/metabolism, Female, Early Detection of Cancer/methods, extracellular vesicles, Cytology, Carcinoma, Pancreatic Ductal/diagnosis, Carcinoma, Pancreatic Ductal

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40241173
https://doaj.org/article/b4cd5088cd7047809e32e0abd7199185
https://curis.ku.dk/ws/files/449312105/Use_of_the_Malaria_Protein_VAR2CSA.pdf

Sphingosine is involved in PAPTP-induced death of pancreas cancer cells by interfering with mitochondrial functions

Autoren: Patel, Sameer H. Wilson, Gregory C. Wu, Yuqing et al.

Quelle: J Mol Med (Berl)

Schlagwörter: 0301 basic medicine, 0303 health sciences, Kv1.3 Potassium Channel, Cell Death, Medizin, Mitochondria, Cell Line, Tumor [MeSH], Proto-Oncogene Proteins p21(ras)/metabolism [MeSH], Pancreatic Neoplasms/pathology [MeSH], Proto-Oncogene Proteins p21(ras)/genetics [MeSH], Original Article, Cell Death/drug effects [MeSH], Kv1.3, Kv1.3 Potassium Channel/antagonists, Carcinoma, Pancreatic Ductal/metabolism [MeSH], Pancreatic Neoplasms/genetics [MeSH], Mitochondria/metabolism [MeSH], Humans [MeSH], Kv1.3 Potassium Channel/genetics [MeSH], Kv1.3 Potassium Channel/metabolism [MeSH], Animals [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], Cytochrome C, Carcinoma, Pancreatic Ductal/genetics [MeSH], Sphingosine/analogs, Carcinoma, Pancreatic Ductal/drug therapy [MeSH], Mice [MeSH], Pancreas cancer, Sphingosine/metabolism [MeSH], Carcinoma, Pancreatic Ductal/pathology [MeSH], Mitochondria/drug effects [MeSH], Pancreatic Neoplasms/metabolism [MeSH], Sphingosine, 3. Good health, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mice, 03 medical and health sciences, Cell Line, Tumor, Humans, Animals, Carcinoma, Pancreatic Ductal

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38780771
https://hdl.handle.net/11577/3515924
https://doi.org/10.1007/s00109-024-02456-2
https://repository.publisso.de/resource/frl:6518160
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85193940138
https://www.ncbi.nlm.nih.gov/pubmed/38780771
https://doi.org/10.1007/s00109-024-02456-2

External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

Autoren: Paul van der Leest Pim Rozendal John Hinrichs et al.

Weitere Verfasser: Paul van der Leest Pim Rozendal John Hinrichs et al.

Quelle: Clinical chemistry : international journal of laboratory medicine and molecular diagnostics
van der Leest, P, Rozendal, P, Pathology, Symbiant B.V., Alkmaar, D, van Noesel, C J M, Zwaenepoel, K, Deiman, B, Huijsmans, C J J, van Eijk, R, Speel, E J M, van Haastert, R J, Ligtenberg, M J L, van Schaik, R H N, Jansen, M P H M, Dubbink, H J, de Leng, W W, Leers, M P G, Tamminga, M, van den Broek, D, van Kempen, L C & Schuuring, E 2024, 'External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium', Clinical Chemistry, vol. 70, no. 5, pp. 759-767. https://doi.org/10.1093/clinchem/hvae014

Schlagwörter: Proto-Oncogene Proteins B-raf, 0301 basic medicine, ErbB Receptors/genetics, Neoplasms/genetics, Circulating Tumor DNA, 3. Good health, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), ErbB Receptors, Circulating Tumor DNA/blood, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Proto-Oncogene Proteins B-raf/genetics, Mutation, Journal Article, Humans, LIQUID BIOPSY, Human medicine, Netherlands

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38484302
https://research.tue.nl/en/publications/ca1642a8-3ddd-4851-9aaf-4aa1224f6f6a
https://doi.org/10.1093/clinchem/hvae014
https://hdl.handle.net/11370/a174bbbb-2574-4fab-b25f-ad1a12929fc2
https://doi.org/10.1093/clinchem/hvae014
https://research.rug.nl/en/publications/a174bbbb-2574-4fab-b25f-ad1a12929fc2
https://dspace.library.uu.nl/handle/1874/453466
https://pure.amsterdamumc.nl/en/publications/997e6477-3569-4554-9ec3-55cd468b14c6
https://doi.org/10.1093/clinchem/hvae014
https://repository.uantwerpen.be/docstore/d:irua:22625
https://hdl.handle.net/10067/2046040151162165141

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

Autoren: Karapetis, C.S. Liu, H. Sorich, M.J. et al.

Weitere Verfasser: Karapetis, C.S. Liu, H. Sorich, M.J. et al.

Quelle: Br J Cancer
The British journal of cancer

Schlagwörter: Proto-Oncogene Proteins B-raf, 0301 basic medicine, PHASE-3, Cetuximab, GUIDELINES, THERAPY, Article, PANITUMUMAB, 1117 Public Health and Health Services, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, Colon cancer, Prognostic markers, Targeted therapies, 0302 clinical medicine, 3211 Oncology and carcinogenesis, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, WILD-TYPE, COMBINATION, Science & Technology, Rectal Neoplasms, Liver Neoplasms, Antibodies, Monoclonal, CHEMOTHERAPY, CETUXIMAB, FLUOROURACIL, 3. Good health, [SDV] Life Sciences [q-bio], ErbB Receptors, 1ST-LINE TREATMENT, Oncology, Colonic Neoplasms, Mutation, Mutation [MeSH], 692/699/67/1504/1885/1393, Proto-Oncogene Proteins B-raf/genetics [MeSH], Antibodies, Monoclonal/therapeutic use [MeSH], Cetuximab [MeSH], Humans [MeSH], Colorectal Neoplasms/drug therapy [MeSH], ErbB Receptors/genetics [MeSH], Fluorouracil [MeSH], Rectal Neoplasms/drug therapy [MeSH], Proto-Oncogene Proteins p21(ras)/genetics [MeSH], Colonic Neoplasms/drug therapy [MeSH], 692/308/53/2422, Colorectal Neoplasms/pathology [MeSH], Colorectal Neoplasms/genetics [MeSH], 631/67/1059/602, Liver Neoplasms/drug therapy [MeSH], article, Human medicine, Fluorouracil, Colorectal Neoplasms, Life Sciences & Biomedicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38402342
https://repository.uantwerpen.be/docstore/d:irua:22806
https://hdl.handle.net/10067/2048770151162165141
https://repository.publisso.de/resource/frl:6523384

Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors

Autoren: Marcell Baranyi Eszter Molnár Luca Hegedűs et al.

Quelle: Br J Cancer

Schlagwörter: 0301 basic medicine, 0303 health sciences, Lung Neoplasms, Medizin, Adenocarcinoma of Lung, Adenocarcinoma, Article, 3. Good health, Adenocarcinoma of Lung [MeSH], Pancreatic Neoplasms/genetics [MeSH], Mutation [MeSH], Humans [MeSH], Lung Neoplasms/genetics [MeSH], Colorectal Neoplasms/drug therapy [MeSH], Animals [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], 631/67/1612, Proto-Oncogene Proteins p21(ras)/genetics [MeSH], Enzyme Inhibitors/pharmacology [MeSH], Adenocarcinoma/drug therapy [MeSH], Adenocarcinoma/genetics [MeSH], Transferases [MeSH], 631/67/1504, Colorectal Neoplasms/genetics [MeSH], 631/67/1059, Lung Neoplasms/drug therapy [MeSH], Disease Models, Animal [MeSH], article, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Disease Models, Animal, 03 medical and health sciences, Transferases, Mutation, Humans, Animals, Enzyme Inhibitors, Colorectal Neoplasms

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38278976
https://repository.publisso.de/resource/frl:6518913
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85183191581
https://doi.org/10.1038/s41416-024-02586-x
https://www.ncbi.nlm.nih.gov/pubmed/38278976

High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma

Autoren: Sönke Detlefsen Henning Bünsow Boldt Mark Burton et al.

Quelle: Human Pathology. 142:68-80

Schlagwörter: Chromosome Aberrations, Adenocarcinoma/pathology, DNA Copy Number Variations, Pancreatic Ductal/genetics, Carcinoma, Pancreatic cancer, Adenocarcinoma, DNA Methylation, Pancreatic Neoplasms/genetics, Prognosis, 3. Good health, Copy number variation (CNV), Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms, Subtyping, Mutation, Next-generation sequencing, Humans, Carcinoma, Pancreatic Ductal

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37977512

Molecular determinants of sotorasib clinical efficacy in KRAS G12C -mutated non-small-cell lung cancer

Autoren: Skoulidis, Ferdinandos Li, Bob T. de Langen, Adrianus Johannes et al.

Quelle: Skoulidis, F, Li, B T, de Langen, A J, Hong, D S, Lena, H, Wolf, J, Dy, G K, Curioni Fontecedro, A, Tomasini, P, Velcheti, V, van der Wekken, A J, Dooms, C, Paz-Ares Rodriguez, L, Mountzios, G, Sacher, A, Nadal, E, Couraud, S, Kim, S W, O’Byrne, K, Rocco, D, Toyozawa, R, Chmielewska, I, Lindsay, C R, Hindoyan, A, Mukundan, L, Wilmanski, T, Anderson, A, Ardito-Abraham, C, Pati, A, Reddy, A, Mehta, B & Schuler, M 2025, 'Molecular determinants of sotorasib clinical efficacy in KRAS G12C -mutated non-small-cell lung cancer', Nature Medicine, vol. 31, no. 8, 110993, pp. ....

Schlagwörter: Humans, Carcinoma, Non-Small-Cell Lung/genetics, Proto-Oncogene Proteins p21(ras)/genetics, Lung Neoplasms/drug therapy, Mutation, Pyrimidines/therapeutic use, Kelch-Like ECH-Associated Protein 1/genetics, Docetaxel/therapeutic use, NF-E2-Related Factor 2/genetics, DNA-Binding Proteins/genetics, Antineoplastic Agents/therapeutic use, Transcription Factors/genetics, Precision Medicine, Piperazines/therapeutic use, Female, Prognosis, Treatment Outcome, Male, Pyridines

Verfügbarkeit: https://research.manchester.ac.uk/en/publications/f4082985-4762-40fd-9dcd-f0894220e229
https://doi.org/10.1038/s41591-025-03732-5
http://www.scopus.com/inward/record.url?scp=105006913721&partnerID=8YFLogxK

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Autoren: Ofra Novoplansky Sankar Jagadeeshan Manu Prasad et al.

Quelle: J Exp Clin Cancer Res
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-23 (2024)
Journal of Experimental & Clinical Cancer Research, vol 43, iss 1

Schlagwörter: KRASG12C mutation, 0301 basic medicine, HER signaling, Oncology and Carcinogenesis, Immunology, Programmed Cell Death 1 Receptor, Drug Resistance, Sotorasib, Cell Line, Proto-Oncogene Proteins p21(ras), Mice, 03 medical and health sciences, Rare Diseases, Cell Line, Tumor, 2.1 Biological and endogenous factors, Animals, Humans, Dental/Oral and Craniofacial Disease, Head and neck cancer, RC254-282, Cancer, 0303 health sciences, Tumor, Biomedical and Clinical Sciences, Cell Line, Tumor [MeSH], Mutation [MeSH], Proto-Oncogene Proteins p21(ras)/metabolism [MeSH], Cell-autonomous, KRAS, Humans [MeSH], Head and Neck Neoplasms/genetics [MeSH], Head and Neck Neoplasms/metabolism [MeSH], Animals [MeSH], Tumor microenvironment, Drug resistance, Head and Neck Neoplasms/drug therapy [MeSH], Programmed Cell Death 1 Receptor/antagonists, Proto-Oncogene Proteins p21(ras)/genetics [MeSH], PD-L1/PD1, Programmed Cell Death 1 Receptor/metabolism [MeSH], Mice [MeSH], Research, Adagrasib, Drug Resistance, Neoplasm [MeSH], Head and Neck Neoplasms/pathology [MeSH], KRAS(G12C) mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Oncology and carcinogenesis, 5.1 Pharmaceuticals, Head and Neck Neoplasms, Drug Resistance, Neoplasm, Mutation, Neoplasm, Immunotherapy

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39567998
https://doaj.org/article/c4597987045c4368ad8d1ce46434bbc8
https://repository.publisso.de/resource/frl:6513622
https://escholarship.org/content/qt0bq0p8k9/qt0bq0p8k9.pdf
https://escholarship.org/uc/item/0bq0p8k9

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

Autoren: McDaid, W J Wilson, L Adderley, H et al.

Quelle: Mol Cancer
Molecular Cancer, Vol 23, Iss 1, Pp 1-18 (2024)
McDaid, W J, Wilson, L, Adderley, H, Martinez-Lopez, A, Baker, M J, Searle, J, Ginn, L, Budden, T, Aldea, M, Marinello, A, Aredo, J V, Viros, A, Besse, B, Wakelee, H A, Blackhall, F, Castillo-Lluva, S, Lindsay, C R & Malliri, A 2024, 'The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer', Molecular Cancer, vol. 23, no. 1, pp. 253. https://doi.org/10.1186/s12943-024-02157-x

Schlagwörter: 0301 basic medicine, Lung Neoplasms, TOR Serine-Threonine Kinases/metabolism, NSCLC, Non-Small-Cell Lung/metabolism, Cell Line, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Mice, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, Signal Transduction/drug effects, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Proto-Oncogene Proteins c-akt/metabolism, KRAS, Animals, Humans, RC254-282, 0303 health sciences, Carcinoma, Non-Small-Cell Lung/metabolism, Tumor, Animal, Research, TOR Serine-Threonine Kinases, Carcinoma, KRASG12D inhibition, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, PI3K-AKT-mTOR pathway, Disease Models, Animal, Disease Models, Mutation, Lung Neoplasms/metabolism, Phosphatidylinositol 3-Kinases/metabolism, Proto-Oncogene Proteins c-akt, Signal Transduction

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39533328
https://doaj.org/article/175d4ffa97f048a68d951ca757e5b52e

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Autoren: Sacher, Adrian LoRusso, Patricia Patel, Manish R et al.

Weitere Verfasser: Sacher, Adrian LoRusso, Patricia Patel, Manish R et al.

Quelle: New England Journal of Medicine. 389:710-721

Schlagwörter: Lung Neoplasms/genetics, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/drug therapy, KRAS protein, human, Oncologie, Administration, Oral, Antineoplastic Agents, Sciences de la santé humaine, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Carcinoma, Non-Small-Cell Lung/genetics, Carcinoma, Non-Small-Cell Lung, Genetics, Humans, Human health sciences, Enzyme Inhibitors, Non-Small-Cell Lung, Lung Neoplasms/drug therapy, Treatments in Oncology, Cancer, Enzyme Inhibitors/therapeutic use, Pulmonary/Critical Care General, Medicine (all), Carcinoma, Lung Cancer, Antineoplastic Agents/therapeutic use, Gastroenterology, Colorectal Neoplasms/drug therapy, Antineoplastic Agents/adverse effects, General Medicine, Enzyme Inhibitors/adverse effects, Hematology/Oncology, Colorectal Neoplasms/genetics, Antineoplastic Agents/administration & dosage, 3. Good health, Pulmonary/Critical Care, Oncology, Enzyme Inhibitors/administration & dosage, Mutation, Colorectal Neoplasms, Gastrointestinal Tract Cancer

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37611121
https://hdl.handle.net/11568/1233168
https://doi.org/10.1056/NEJMoa2303810
https://discovery-pp.ucl.ac.uk/id/eprint/10176284/

Synergy and Anti-Cooperativity in Allostery: Molecular Dynamics Study of WT and Oncogenic KRAS-RGL1

Autoren: Aysima Hacisuleyman Burak Erman

Quelle: Proteins, vol. 92, no. 5, pp. 665-678

Schlagwörter: Proto-Oncogene Proteins p21(ras), Humans, Molecular Dynamics Simulation, Proto-Oncogene Proteins p21(ras)/genetics, Mutation, Neoplasms/genetics, Allosteric Regulation, Guanine Nucleotide Exchange Factors, Allostery, anti‐cooperativity, dynamic allostery, interaction information, molecular dynamics, mutual information, oncogenic mutation, synergy, three‐body interactions, Neoplasms, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38153169
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_87CA828A4D758
https://serval.unil.ch/resource/serval:BIB_87CA828A4D75.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_87CA828A4D75

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

Autoren: Grace K. Dy Ramaswamy Govindan Vamsidhar Velcheti et al.

Quelle: J Clin Oncol

Schlagwörter: Lung Neoplasms, PHASE-3, NF-E2-Related Factor 2, Medizin, INHIBITION, Lung Neoplasms / drug therapy, Proto-Oncogene Proteins p21(ras), 3211 Oncology and carcinogenesis, Carcinoma, Non-Small-Cell Lung, Medicine and Health Sciences, Carcinoma, Non-Small-Cell Lung / genetics, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Non-Small-Cell Lung, Lung Neoplasms / genetics, DOCETAXEL, Science & Technology, Kelch-Like ECH-Associated Protein 1, Carcinoma, ICTS (Institute of Clinical and Translational Sciences), NIVOLUMAB, 1103 Clinical Sciences, 3. Good health, CLINICAL TRIAL UPDATES, TRIALS, Oncology, Proto-Oncogene Proteins p21(ras) / genetics, Carcinoma, Non-Small-Cell Lung / drug therapy, Life Sciences & Biomedicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37098232
https://lirias.kuleuven.be/handle/20.500.12942/719125
https://doi.org/10.1200/jco.22.02524
https://archive-ouverte.unige.ch/unige:179210
https://doi.org/10.1200/jco.22.02524

Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Autoren: Catherine Lee Ziyue Karen Jiang Simon Planken et al.

Weitere Verfasser: Catherine Lee Ziyue Karen Jiang Simon Planken et al.

Quelle: Mol Cancer Ther

Schlagwörter: Models and Technologies, mice, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung/drug therapy, Transplantation, Heterologous, 3. Good health, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), Mice, Disease Models, Animal, Carcinoma, Non-Small-Cell Lung, Mutation, Animals, Humans, Heterografts, mutation, Lung Neoplasms/drug therapy

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37186518
https://biblio.vub.ac.be/vubir/efficacy-and-imagingenabled-pharmacodynamic-profiling-of-kras-g12c-inhibitors-in-xenograft-and-genetically-engineered-mouse-models-of-cancer(27a40279-cb02-4528-8692-976449153a3d).html

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial: a randomised, open-label, phase 3 trial

Autoren: de Langen, Adrianus Johannes Johnson, Melissa L Mazieres, Julien et al.

Weitere Verfasser: de Langen, Adrianus Johannes Johnson, Melissa L Mazieres, Julien et al.

Quelle: CodeBreaK 200 Investigators 2023, 'Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation : a randomised, open-label, phase 3 trial', Lancet (London, England), vol. 401, no. 10378, pp. 733-746. https://doi.org/10.1016/S0140-6736(23)00221-0

Schlagwörter: Adult, Lung Neoplasms, Adolescent, Carcinoma, Non-Small-Cell Lung/drug therapy, Carcinoma, Antineoplastic Agents/therapeutic use, Non-Small-Cell Lung/drug therapy, Antineoplastic Agents, Docetaxel, Sotorasib versus docetaxel, non-small-cell lung cancer, KRASG12C mutation, open-label, phase 3 trial, Disease-Free Survival, 3. Good health, Proto-Oncogene Proteins p21(ras)/genetics, Proto-Oncogene Proteins p21(ras), 03 medical and health sciences, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, SDG 3 - Good Health and Well-being, Carcinoma, Non-Small-Cell Lung, Mutation, Antineoplastic Combined Chemotherapy Protocols, Humans, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Lung Neoplasms/drug therapy, Docetaxel/therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36764316
https://research.manchester.ac.uk/en/publications/bb34c9db-1233-4f81-891d-c1292da56ffb
https://doi.org/10.1016/S0140-6736(23)00221-0
https://research.rug.nl/en/publications/d873b7f1-db46-4bc7-8b12-c0a27d769cb5
https://doi.org/10.1016/S0140-6736(23)00221-0
https://hdl.handle.net/11370/d873b7f1-db46-4bc7-8b12-c0a27d769cb5
https://hal.science/hal-04989148v1
https://doi.org/10.1016/s0140-6736(23)00221-0
https://research.manchester.ac.uk/en/publications/bb34c9db-1233-4f81-891d-c1292da56ffb
http://www.scopus.com/inward/record.url?scp=85149232815&partnerID=8YFLogxK
https://doi.org/10.1016/S0140-6736(23)00221-0
https://hdl.handle.net/2318/1892253
https://doi.org/10.1016/S0140-6736(23)00221-0

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Autoren: Klara Dorman Danmei Zhang Kathrin Heinrich et al.

Quelle: Target Oncol

Schlagwörter: Proto-Oncogene Proteins p21(ras), Pancreatic Neoplasms, Mutation, Humans, Pancreatic Neoplasms [MeSH], Pancreatic Neoplasms/genetics [MeSH], Medical and Health Sciences, Mutation [MeSH], Humans [MeSH], Original Research Article, Precision Medicine/methods [MeSH], Retrospective Studies [MeSH], Molecular Targeted Therapy/methods [MeSH], Pancreatic Neoplasms/drug therapy [MeSH], Proto-Oncogene Proteins p21(ras)/genetics [MeSH], Molecular Targeted Therapy, Precision Medicine, 3. Good health, Retrospective Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36853374
https://repository.publisso.de/resource/frl:6484965
https://epub.ub.uni-muenchen.de/116364/